rs79987078
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM2PP5
The NM_014270.5(SLC7A9):c.368C>T(p.Thr123Met) variant causes a missense change. The variant allele was found at a frequency of 0.000236 in 1,614,210 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00022 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00024 ( 0 hom. )
Consequence
SLC7A9
NM_014270.5 missense
NM_014270.5 missense
Scores
1
11
7
Clinical Significance
Conservation
PhyloP100: 5.44
Genes affected
SLC7A9 (HGNC:11067): (solute carrier family 7 member 9) This gene encodes a protein that belongs to a family of light subunits of amino acid transporters. This protein plays a role in the high-affinity and sodium-independent transport of cystine and neutral and dibasic amino acids, and appears to function in the reabsorption of cystine in the kidney tubule. Mutations in this gene cause non-type I cystinuria, a disease that leads to cystine stones in the urinary system due to impaired transport of cystine and dibasic amino acids. Alternate transcript variants, which encode the same protein, have been found for this gene. [provided by RefSeq, Jul 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 19-32864206-G-A is Pathogenic according to our data. Variant chr19-32864206-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 5793.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=3, Uncertain_significance=2, Pathogenic=4}. Variant chr19-32864206-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC7A9 | NM_014270.5 | c.368C>T | p.Thr123Met | missense_variant | 4/13 | ENST00000023064.9 | NP_055085.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC7A9 | ENST00000023064.9 | c.368C>T | p.Thr123Met | missense_variant | 4/13 | 1 | NM_014270.5 | ENSP00000023064 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000210 AC: 32AN: 152232Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
32
AN:
152232
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000195 AC: 49AN: 251344Hom.: 0 AF XY: 0.000147 AC XY: 20AN XY: 135874
GnomAD3 exomes
AF:
AC:
49
AN:
251344
Hom.:
AF XY:
AC XY:
20
AN XY:
135874
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000238 AC: 348AN: 1461860Hom.: 0 Cov.: 34 AF XY: 0.000226 AC XY: 164AN XY: 727222
GnomAD4 exome
AF:
AC:
348
AN:
1461860
Hom.:
Cov.:
34
AF XY:
AC XY:
164
AN XY:
727222
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000217 AC: 33AN: 152350Hom.: 0 Cov.: 33 AF XY: 0.000188 AC XY: 14AN XY: 74506
GnomAD4 genome
AF:
AC:
33
AN:
152350
Hom.:
Cov.:
33
AF XY:
AC XY:
14
AN XY:
74506
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
17
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:8Uncertain:4
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Cystinuria Pathogenic:7Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 22, 2021 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2007 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 28, 2023 | Variant summary: SLC7A9 c.368C>T (p.Thr123Met) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00019 in 251344 control chromosomes (gnomAD). c.368C>T has been reported in the literature in multiple individuals affected with Cystinuria, including at least four individuals with a biallelic genotype (e.g. Font_2001, Skopkov_2005, Wong_2015, Gaildrat_2017, Alghamdi_2020, Domingo-Gallego_2022). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 33262960, 33532864, 11157794, 28717662, 16138908, 25109415). Six submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 and classified it as either pathogenic (n=3)/likely pathogenic (n=2) or VUS (n=1). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Sep 07, 2018 | The SLC7A9 c.368C>T (p.Thr123Met) variant has been reported in at least six studies and is found in a total of ten individuals including one in a homozygous state, five in a compound heterozygous state including one sibling pair, and four in a heterozygous state. (Font et al. 2001; Font-Llitjos et al. 2005; Skopkova et al. 2005; Eggermann et al. 2007; Bisceglia et al. 2010). All individuals presented with type I or non-type I phenotypes, and this variant is suggested to be associated with a mild form of the disease (Font et al. 2001). The p.Thr123Met variant was absent from 100 control chromosomes, but is reported at a frequency of 0.000378 in the Latino population of the Genome Aggregation Database. This variant is located in a transmembrane domain of the SLC7A9 protein (Font et al. 2001). Structurally, the p.Thr123Met variant is predicted to alter the hydrogen bond between the Thr123 and Thr121 residue (Martell et al. 2017). While cystinuria generally displays an autosomal recessive mode of inheritance, some heterozygous carriers of variants in the SLC7A9 gene have abnormal urinary amino acid patterns and an increased risk of kidney stones (Eggermann et al. 2012). Based on the collective evidence, the p.Thr123Met variant is classified as pathogenic for cystinuria. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 29, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | research | Molecular Biology Laboratory, Fundació Puigvert | Feb 01, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Nov 30, 2021 | ACMG classification criteria: PS3 supporting, PS4 strong, PM2 moderate, PM3 strong, PP1 supporting - |
not provided Pathogenic:1Uncertain:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 23, 2021 | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 123 of the SLC7A9 protein (p.Thr123Met). This variant is present in population databases (rs79987078, gnomAD 0.04%). This missense change has been observed in individual(s) with non-type 1 cystinuria (PMID: 16138908, 19782624, 25964309, 28717662). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 5793). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C15"). For these reasons, this variant has been classified as Pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 25, 2024 | Observed in apparent homozygous state in patients with cystinuria in the literature and not observed in homozygous state in controls (PMID: 16138908, 33262960); Observed with a second SLC7A9 variant in individuals with cystinuria in the published literature, but it is not known whether the variants occurred on the same (in cis) or on different (in trans) chromosomes in most cases (PMID: 17539912, 19782624, 28717662, 33349102, 33532864, 25964309); Associated with a range of amino acid excretion patterns, from nearly normal to hyperexcretion of cystine, in individuals harboring this variant in the heterozygous state (PMID: 22480232, 15635077); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 28717662, 28812535, 28270646, 25109415, 20981092, 11157794, 26990548, 6031738, 12234283, 12036192, 22480232, 15635077, 19782624, 31589614, 33532864, 14991253, 16834950, 33262960, 25964309, 33349102, 16138908, 17539912) - |
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Uncertain
DEOGEN2
Uncertain
D;D;D
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;.;D
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Benign
L;L;L
MutationTaster
Benign
A;A;A
PrimateAI
Benign
T
PROVEAN
Benign
.;N;.
REVEL
Uncertain
Sift
Benign
.;D;.
Sift4G
Uncertain
D;D;D
Polyphen
B;B;B
Vest4
MVP
MPC
0.84
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at